Euclidean Capital related stories
All articles and analysis
ASAPP nets $185m Series BNew York-based ASAPP Inc, an artificial intelligence company, has closed $185 million in Series B funding.
Dascena lands $50m Series BOakland, California-based Dascena Inc, a machine learning diagnostic algorithm company, has raised $50 million in Series B financing.
- Kallyope picks up $112m Series C
New York City-based Kallyope Inc., a biotechnology company, has secured $112 million in Series C financing.
- Codagenix lands $20 mln Series B
Farmingdale, New York-based Codagenix Inc, a developer of prophylactic vaccines and oncolytic virus therapies, has raised $20 million in Series B funding.
ArsenalBio scores $85 mln Series ASouth San Francisco-based ArsenalBio, a developer of a cell therapy company, has secured $85 million in Series A financing. The investors included Westlake Village BioPartners, the Parker Institute for Cancer Immunotherapy, Kleiner Perkins, the University of California, San Francisco Foundation Investment Company, Euclidean Capital and Osage Venture Partners.
- Peltarion attracts $20 mln Series A
Peltarion, a Swedish operational AI company, has raised $20 million in Series A financing. Euclidean Capital led the round with participation from FAM and EQT Ventures.
- VC-backed biotech company Alector goes public
South San Francisco-based Alector Inc, a biotechnology company focused on treating neurodegeneration, has raised $176 million for its IPO after pricing its 9.25 million shares at $19 per share. The stock began trading February 7, 2019 on the NASDAQ under the ticker symbol "ALEC." Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays are the lead underwriters. Alector's pre-IPO backers include Deerfield Management, AbbVie Ventures, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, Lilly Asia Ventures, New Leaf Venture Partners, Polaris Partners, OrbiMed, MRL Ventures, GV and the Dementia Discovery Fund.
- Ribon Therapeutics lands $65 mln Series B
Lexington, Massachusetts-based Ribon Therapeutics, a biotechnology company, has raised $65 million in Series B financing. Novartis Venture Fund led the round with participation from JJDC, Celgene Corporation, The Column Group, Deerfield Management, U.S. Venture Partners, Osage University Partners, Takeda Ventures and Euclidean Capital.
- Kallyope snags $21 mln
New York City-based Kallyope Inc., a biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, has secured $21 million in funding. The lead investor was Bill Gates. Other investors included Lux Capital, The Column Group, Polaris Partners, Illumina Ventures, Alexandria Venture Investments, Euclidean Capital and Two Sigma Ventures.
- Alector Inc racks up $133 mln
South San Francisco-based Alector Inc, a biotechnology company focused on developing therapies that harness the immune system to cure neurodegenerative diseases and cancer, has raised $133 million in Series E financing. The investors included Deerfield Management, AbbVie Ventures, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, Lilly Asia Ventures, New Leaf Venture Partners, Polaris Partners, OrbiMed, MRL Ventures, GV and the Dementia Discovery Fund.